Terms ending in 2033
Every in-force patent on Ipsen Biopharm Ltd.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,339,497 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · High confidence | Ipsen Biopharm Ltd. | In force | High confidence | |
| US 9,364,473 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | |
| US 9,452,162 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | |
| US 9,492,442 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | |
| US 9,717,724 | Methods for Treating Pancreatic Cancer Using Combination Therapies In force · Low confidence | Ipsen Biopharm Ltd. | In force | Low confidence | |
| US 10,980,795 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | |
| US 11,369,597 | Methods For Treating Pancreatic Cancer Using Combination Therapies In force · Low confidence | Ipsen Biopharm Ltd. | In force | Low confidence | |
| US 10,030,238 | Recombinant Clostridium Botulinum Neurotoxins In force · High confidence | Ipsen Bioinnovation Limited and Ipsen Biopharm Limited | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.